Corvus Pharmaceuticals Inc. (NASDAQ: CRVS)
$4.8950
+0.3450 ( +7.35% ) 450.3K
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Market Data
Open
$4.8950
Previous close
$4.5500
Volume
450.3K
Market cap
$296.23M
Day range
$4.4600 - $4.8980
52 week range
$1.3000 - $10.0000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 23, 2024 |
4 | Insider transactions | 1 | Dec 23, 2024 |
4 | Insider transactions | 1 | Dec 23, 2024 |
4 | Insider transactions | 1 | Dec 23, 2024 |
8-k | 8K-related | 19 | Dec 18, 2024 |
8-k | 8K-related | 15 | Nov 12, 2024 |
10-q | Quarterly Reports | 77 | Nov 12, 2024 |
8-k | 8K-related | 14 | Oct 23, 2024 |
8-k | 8K-related | 16 | Aug 06, 2024 |
10-q | Quarterly Reports | 76 | Aug 06, 2024 |